Early phase studies have demonstrated remarkable responses in patients with advanced ES treated with an insulin-like growth factor-1 receptor (IGF1R) antibody, with or without an mTOR inhibitor, albeit in only a small subset (10–14%) of individuals [1], [8], [9], [10], [11], [12], [13]. The gene discussed is IGF1R; the disease is Ewing sarcoma.